Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Hu6.0
Huperzin A – Forschung
Hilft wahrscheinlich
57 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Huperzin A sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 1991–2026 mit einer typischen Studiengröße von 194 Teilnehmenden.
Basierend auf 57 Studien · 11 Meta-Analysen · 13 RCTs · 57,240 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Was die Studien gefunden haben
2geholfen· 55 weitere ohne bewertete Effektdaten
Nach Outcome
Cognitive functionAcetylcholinesterase-Hemmer; Gedächtnisnutzen hauptsächlich in Demenzstudien von unterschiedlicher Qualität gezeigt · 2-4 Wochen
Patients with Alzheimer's disease and vascular dementia1
Alzheimer's disease participants1
Aktives Forschungsgebiet
23 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2024
199120082026
1MMSE and ADL scores in patients with Alzheimer's disease and vascular dementiaMeta-Analysen=825 · large study2014
Einfach gesagt: Hup A is a well-tolerated drug that could significantly improve cognitive performance in patients with AD or VD, but we need to use it with caution in the clinical treatment.
Xing SH et al. · Evidence-based complementary and alternative medicine : eCAM (2014)
Hup A could significantly improve the MMSE and ADL score of AD and VD patients, and longer durations would result in better efficacy for the patients with AD.
Benefits observed in both Alzheimer's and vascular dementia
Most adverse effects in AD were generally of mild to moderate severity and transient; Hup A may offer fewer side effects for participants with VD.
2Cognitive function improvement with Huperzine AMeta-Analysen=1,823 · large study2013
Einfach gesagt: Huperzine A appears to have beneficial effects on improvement of cognitive function, daily living activity, and global clinical assessment in participants with Alzheimer's disease.
Yang G et al. · PloS one (2013)
Huperzine A appears to have beneficial effects on improvement of cognitive function, daily living activity, and global clinical assessment in participants with Alzheimer's disease.
However, the findings should be interpreted with caution due to the poor methodological quality of the included trials.
4Traditional Chinese herbal medicine effects on vascular dementiaSystematische Übersichtn=3,581 · very large study2018
Einfach gesagt: We found moderate- to very low-quality evidence of benefit and harm of TCHMs for VaD.
Chan ES et al. · The Cochrane database of systematic reviews (2018)
Two TCHMs (NaoMaiTai and TongXinLuo) had a 5% or more increased risk of AEs compared to the 'no Treatment' control, but the quality of this evidence was poor.
We found moderate- to very low-quality evidence of benefit and harm of TCHMs for VaD.
Methodological inadequacies need to be addressed by better conducted and reported trials.
6Alzheimer's drug discovery approaches evaluationSystematische Übersichtn=100 · medium study2025
Azmal M et al. · Journal of computer-aided molecular design (2025)
Computational approaches significantly expedite the identification and optimization of AD drug candidates by enabling the rapid screening of extensive compound libraries.
These methods, when combined with experimental validations, offer deeper molecular-level insights into drug interactions and mechanisms.
However, challenges such as predictive accuracy and data quality remain, necessitating further advancements in computational models and data integration to improve the predictability and effectiveness of AD therapeutics.
10Cognitive function and activities of daily living in AD patientsSystematische Übersichtn=149 · medium study2022
Einfach gesagt: Our study demonstrated that AChE inhibitors, Ginkgo biloba, and cerebrolysin are the optimum cognitive and activities of daily living medication for patients with AD.
Fan F et al. · Journal of Alzheimer's disease : JAD (2022)
Our study demonstrated that AChE inhibitors, Ginkgo biloba, and cerebrolysin are the optimum cognitive and activities of daily living medication for patients with AD.
11Functional decline delay in dementiaSystematische Übersichtn=289 · medium study2016
Einfach gesagt: Healthcare professionals should ensure that people with dementia are encouraged to exercise and that primary carers are trained and supported to provide safe and effective care for the person with dementia.
Laver K et al. · BMJ open (2016)
The quality of the reviews varied; however most (65%) scored 8/11 or more on the AMSTAR tool, indicating high quality.
Healthcare professionals should ensure that people with dementia are encouraged to exercise and that primary carers are trained and supported to provide safe and effective care for the person with dementia.
Acetylcholinesterase inhibitors or memantine should be trialled unless contraindicated.
12Over the counter supplements effects on memoryÜbersicht2023
Hersant H et al. · CNS drugs (2023)
More rigorous studies are needed relative to the long-term use of these supplements in homogenous populations with standardized measurements of cognition.
Health care providers need to be aware of any and all supplements their older adult patients may be consuming and be educated about their side effects and interactions with prescription medications.
Lastly, the FDA needs to take an active position relative to monitoring marketed supplements regarding safety, purity and claims of efficacy.
13Cognitive impairment treatment in Parkinson's diseaseÜbersicht2023
Einfach gesagt: Finally, we aim to provide additional insights and propose new ideas for investigation that may be feasible and effective for the spectrum of PD-related cognitive impairment.
Degirmenci Y et al. · Medicina (Kaunas, Lithuania) (2023)
In this updated overview, we aim to cover the clinical aspects of the spectrum of PD-related cognitive impairment and discuss recent evidence on emerging treatment approaches that are under investigation at a preclinical and clinical level.
14Neuroprotective effects in Alzheimer's diseaseÜbersicht2021
Einfach gesagt: Our goal is to provide an integrated overview of the molecular mechanisms through which HupA affects AD.
Friedli MJ et al. · Molecules (Basel, Switzerland) (2021)
The effects of this alkaloid have been attributed to its ability to inhibit the cholinergic enzyme acetylcholinesterase (AChE), acting as an acetylcholinesterase inhibitor (AChEI).
The biological functions of HupA have been studied both in vitro and in vivo, and its role in neuroprotection appears to be a good therapeutic candidate for Alzheimer´s disease (AD).
Our goal is to provide an integrated overview of the molecular mechanisms through which HupA affects AD.
15Cognitive function in mild to moderate ADÜbersicht2022
Einfach gesagt: The purpose of this review is to expose the positive results of intervention with EGb 761® and Huperzine in patients with mild to moderate AD in the last 10 years, highlighting the pharmacological functions that justify their use in AD therapy.
Villegas C et al. · IUBMB life (2022)
Currently, there is no successful pharmacological treatment for AD.
The few approved drugs are mainly aimed at treating the symptoms; however, due to the increasing discovery of etiopathological factors, there are great efforts to find new multifunctional molecules to slow down the course of this neurodegenerative disease.
Chauhan PS et al. · CNS & neurological disorders drug targets (2022)
These elements promote cell health, regeneration, and the anti-aging process that specifically interrupt the pathogenic pathways in AD development.
Fortunately, incorporating changes in the nutritional content is inexpensive, easy, acceptable, safe, effective, and in most cases, free from major adverse events.
Many nutritional phytoconstituents such as flavonoids, alkaloids, and terpenoids are still being evaluated in the hope of identifying a successful therapy for AD.
17Cognitive dysfunction in patients with ADMeta-Analysen=33 · small study2019
Einfach gesagt: Evaluation of the clinically common anti-dementia drugs using NMA affirmed the utility of cholinesterase inhibitors, especially donepezil, in alleviating cognitive dysfunction of patients with AD.
Cui CC et al. · Medicine (2019)
Evaluation of the clinically common anti-dementia drugs using NMA affirmed the utility of cholinesterase inhibitors, especially donepezil, in alleviating cognitive dysfunction of patients with AD.
This study may therefore help to inform the clinical selection of pharmacotherapeutic interventions addressing cognitive dysfunction in patients with AD.
18Brain and nerve function protection in Multiple SclerosisSystematische Übersicht2017
Einfach gesagt: Further studies with a focus on the molecular mechanisms of the protective natural compounds are needed to decrease possible side effects and to develop new medicines for MS.
Sanadgol N et al. · Current drug targets (2017)
Further studies with a focus on the molecular mechanisms of the protective natural compounds are needed to decrease possible side effects and to develop new medicines for MS.
Apigenin, chrysin, baicalein, cyanidin, flavone glycoside, daidzein, coumestrol, sulforaphane, bee venom and huperzine A are the candidates for more prospective investigations.
Einfach gesagt: However, there is a need for more robust clinical trials focusing on executive function and other cognitive measures and incorporation of newer imaging modalities to provide additional evidence about the utility of these strategies in patients with VCI.
Farooq MU et al. · CNS drugs (2017)
The benefits of other drugs such as rivastigmine, memantine, nimodipine, and piracetam are not clear.
Some other supplements and herbal therapies, such as citicoline, actovegin, huperzine A, and vinpocetine, have also been studied in patients with VaD, but their beneficial effects are not well established.
Non-drug therapies and lifestyle modifications such as diet, exercise, and vascular risk factor control are important in the management of VCI and should not be ignored.
20Memory quotient (MQ) and MMSE scoresMeta-Analyse2019
Einfach gesagt: Due to the low quality of original studies, more high-quality studies are needed to verify its efficacy.
Huang P et al. · Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica (2019)
The Meta-analysis results showed that compared with placebo, Huperzine significantly increased the scores of memory quotient(MQ) and mini-mental state examination(MMSE).
However, there was no statistical difference between oral tablet and capsule.
Compared with placebo, huperzine A was superior in the scores of MQ and MMSE.